Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma announced it will release its interim report for the first half of 2025 on July 17, 2025, followed by a conference call to discuss the results and provide a business and pipeline update. This event, featuring key company executives, is an opportunity for stakeholders to gain insights into Hansa’s operational progress and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Their portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 219,486
Current Market Cap: SEK2.23B
For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.